Clarus Therapeutics logo — Driven by a mission to help men overcome the health-eroding...

Clarus Therapeutics

Driven by a mission to help men overcome the health-eroding symptoms of hypogonadism

Founded 2004 17 employees Post-IPO Equity Total: $122.00M Biotechnology, Health Care +2

General Information

Company Name Clarus Therapeutics
Founded Year 2004
Employees 17
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Clarus Therapeutics. To contact Clarus Therapeutics, visit clarustherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Clarus Therapeutics compare?

A PDF of Clarus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Clarus Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Clarus Therapeutics

Clarus Therapeutics is a men's specialty pharmaceutical company founded in 2003, driven by a mission to help men overcome the health-eroding symptoms of hypogonadism. Specializing in Biotechnology and Health Care, the company is dedicated to addressing the needs of men with hypogonadism, associated with a deficiency or absence of endogenous testosterone. Backed by prominent investors including Thomas, McNerney & Partners, L.P., H.I.G. BioHealth Partners, ProQuest Investments, C-Bridge Capital Partners, LLC, BVCF Management, Ltd. and Pavilion Capital Pte Ltd., Clarus Therapeutics recently secured a $30.00MPost-IPO Equity investment on 25 April 2022. The company's commitment to making a positive impact on the lives of affected men is evident through its relentless efforts and strong financial backing. For more information, visit them at clarustherapeutics.com.

Business keywords: pharmaceutical company, men's health, hypogonadism, testosterone deficiency, biopharmaceutical, men's specialty medicine, startup, investors, drug development, private company, clinical research, testosterone therapy, health technology

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $30.00M -
25 Apr 2022
Post IPO Equity $15.00M -
03 Dec 2021
Post IPO Equity $25.00M 1
H.I.G. Capital
10 Sep 2021
Venture Round $31.50M 1
C-Bridge Capital
12 Jun 2014
Debt Financing $10.00M 1
Armentum Partners
01 Jan 2013
Series C $8.00M 2
H.I.G. Capital, Thomas, McNerney & Partners
27 Nov 2007
Series B Undisclosed 1
Thomas, McNerney & Partners
01 Mar 2006
Series A $2.50M 1
Thomas, McNerney & Partners
01 Feb 2004

Clarus Therapeutics Alternatives & Competitors

View All Alternatives
Clarus Therapeutics vs

Pioneering advancements in female sexual health, menopause, contraception, and male hypogonadism wit...

Post-IPO Equity
Biotechnology, Health Care
Clarus Therapeutics vs

Pioneering innovative solutions for male hypogonadism, female sexual dysfunction, and respiratory di...

Post-IPO Equity
Biotechnology, Health Care
Clarus Therapeutics vs

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness

FAQ About Clarus Therapeutics

Driven by a mission to help men overcome the health-eroding symptoms of hypogonadism
Clarus Therapeutics was founded in 2004.
Clarus Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on pharmaceutical company, men's health, hypogonadism and testosterone deficiency.
Clarus Therapeutics has approximately 17 employees.
Clarus Therapeutics has completed 8 funding rounds, raising a total of $122.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Clarus Therapeutics include BioSante Pharmaceuticals, Trimel Pharmaceuticals, Lisata Therapeutics, Inc., ObsEva SA, Coeptis Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Clarus Therapeutics and BioSante Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Clarus Therapeutics, https://bouncewatch.com/company/clarus-therapeutics, updated 29 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes